Studies show that among obese people with cardiovascular disease, weight loss jabs can reduce the risk of a heart attack or stroke by a fifth.

Semaglutide, marketed as Wegovy, was the subject of a five-year trial by the pharmaceutical company Novo Nordisk.

The business gathered 17,604 persons over 45 from 41 different countries as part of its Select study.

Each patient did not have a history of diabetes and had a body mass index (BMI) of 27 or above along with established cardiovascular disease.

,weight loss jabs,do weight loss jabs work
,ozempic weight loss jabs
,saxenda weight loss jabs
,celebrity weight loss jabs
,best weight loss jabs
,wegovy weight loss jabs
,weight loss jabs boots,
,weight loss jabs nhs
,weight loss jabs side effects
,weight loss jabs uk
image credit: arabianbusiness

Researchers discovered that individuals who received Wegovy at a dosage of 2.4 mg once weekly along with usual treatment for the prevention of heart attacks or stroke had a 20% lower chance of experiencing one compared to patients who received a placebo.

According to Martin Holst Lange, executive vice president for development at Novo Nordisk, “People with obesity have an increased risk of cardiovascular disease, but to date, there are no approved weight-management medications proven to deliver effective weight management while also reducing the risk of heart attack, stroke, or cardiovascular death.”

We are thus overjoyed with the Select study’s findings showing that semaglutide 2.4mg reduces the risk of cardiovascular events.

Semaglutide 2.4mg has the potential to alter how obesity is considered and handled, as shown by the landmark Select study.

The label indication expansion for Wegovy, according to Novo Nordisk, will be submitted for regulatory approval in the US and the EU in 2023.

The results “have been long awaited and do not disappoint,” according to Professor Stephen O’Rahilly, director of the MRC Metabolic Diseases Unit at the Institute of Metabolic Science, University of Cambridge.

Also read: Use UPI and AI to make conversational payments now

Simply put, if overweight or obese persons take a medicine that works to reduce body weight by targeting hunger over the long term, it greatly lowers their risk of major cardiovascular events like heart attacks.

The logical inference from these results is that we should consider obesity to be a medical illness, similar to high blood pressure, where effective and secure pharmacological therapy can help to reduce major unfavorable health effects.